The RSV vaccine for children — called monoclonal antibody treatment — introduces new antibodies to fight the disease.

Regions Conference approved the immunization plan to protect newborns from respiratory syncytial virus (VRS), one of the main ...

Clesrovimab is an extended half-life RSV neutralizing antibody in development for all infants in their first RSV season and ...

It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory ...

Wall Street promptly began trying to weigh the compound’s marketplace odds after Merck & Co. Inc. detailed positive data from the phase IIb/III trial known as MK-1654-004 with clesrovimab, an ...

The U.S. Food and Drug Administration approved Astellas' therapy to treat a type of gastric cancer, the health regulator's ...

A Phase IIb/III trial with infants entering their first respiratory syncytial virus (RSV) season met its primary endpoints.

Tulisokibart is more effective in inducing clinical remission in patients with moderately to severely active ulcerative colitis than placebo.

Novo Nordisk's Alhemo (concizumab) receives a positive opinion from the EMA's CHMP for hemophilia A or B with inhibitors. The ...

Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV.

Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months.